Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor

For patients with inoperable neuroendocrine tumors (NETs) expressing somatostatin receptors, peptide receptor radionuclide therapy (PRRT) with (177)Lu-[DOTA0-Tyr3]-octreotate ((177)Lu-octreotate) is one of the most promising targeted therapeutic options but it rarely achieves cure. Therefore, differ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Purohit, Nupur K., Shah, Rashmi G., Adant, Samuel, Hoepfner, Michael, Shah, Girish M., Beauregard, Jean-Mathieu
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5973847/
https://ncbi.nlm.nih.gov/pubmed/29872498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25266
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados